

Company Overview

Medipacs is a product development stage medical device company bringing to market a revolutionary new programmable micro-infusion pump that combines the accuracy of electronically controlled infusion pumps with the low cost and convenience of a disposable infusion device, a new category in the infusion pump field.

Product Overview

About the size of a standard pocket watch, and suitable for both inpatient acute care and outpatient ambulatory applications, this new approach to small volume parenteral drug administration is made possible using a completely new, patent-pending polymer-based pumping technology which is electronically controlled. Simple, elegant, low-cost devices result from this technology, yet they have features found in pumps costing 50x more. As such, Medipacs products are poised to be 'disruptive' in served markets.

Intellectual Property

Medipacs has filed patents to protect numerous planned product configurations in key markets and has developed trade secret knowledge pertaining to its unique polymer formulations. Our first patent, filed under PCT, has been allowed in India and we have trade marked and plan to brand our devices with the name Mini-Infuser™.

Market Opportunity

While applications span multiple medical specialties, the MediPacs Mini-infuser™ is already attracting attention from anesthesia, neonatology specialists, insulin delivery and other applications where small volume parenterals must be accurately infused over specific time periods. Market segments the technology serves total over \$6 B and will be addressed through a combination of direct and OEM sales channels.

Management Team

Medipacs has surrounded the founder with a management team and board of directors possessing valuable knowledge, contacts and depth of experience in launching infusion device businesses at Baxter, Cardinal, American Hospital Supply, MiniMed, Block Medical and Medication Delivery Devices. **Mark McWilliams, CEO:** CEO Q3DM (acquired by Beckman Coulter), Founder and COO Medication Delivery Devices (acquired by Baxter)/VP R&D Baxter, Co-Founder Block Medical (acquired by Hillenbrand). **Mark Banister, Founder and CTO:** Founder of three manufacturing companies, Manager Operations Damco. **David Swenson, Clinical and Regulatory Services:** Hospital pharmacist and first product manager at Pyxis, developed cost-benefit sales model that drove 80% market share; founder Intellidot, a medication safety solution for hospitals. **Mark Van Veen, Engineering:** Developed first infusion pumps at IMED. Lead development of HP color ink-jet cartridges and manufacturing processes. **Anthony DeLizza, Marketing:** Tony was Director of Marketing and Business Development at J&J Lifescan, a diabetes monitoring company selling to both consumers and hospitals. **Glen Freiberg, Regulatory Affairs:** Consultant VP Regulatory Affairs Alphatec Spine, Gen-Probe, Bard Diagnostics, Coulter Corp and others.

Financial Summary and Investment

Medipacs is seeking a first institutional equity investment up to \$15M to fund clearance to market from FDA via 510(K), manufacturing partner selection, tooling and working capital, establish a direct sales force and to fund operations through the first year of sales.

